CN1142910C - 酰胺化合物 - Google Patents

酰胺化合物 Download PDF

Info

Publication number
CN1142910C
CN1142910C CNB008027455A CN00802745A CN1142910C CN 1142910 C CN1142910 C CN 1142910C CN B008027455 A CNB008027455 A CN B008027455A CN 00802745 A CN00802745 A CN 00802745A CN 1142910 C CN1142910 C CN 1142910C
Authority
CN
China
Prior art keywords
compound
salt
reaction
dichloromethane
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008027455A
Other languages
English (en)
Chinese (zh)
Other versions
CN1336917A (zh
Inventor
������ɽ����
山田明
青木敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1336917A publication Critical patent/CN1336917A/zh
Application granted granted Critical
Publication of CN1142910C publication Critical patent/CN1142910C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB008027455A 1999-01-14 2000-01-06 酰胺化合物 Expired - Lifetime CN1142910C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8180 1999-01-14
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
AUP8180 1999-01-14

Publications (2)

Publication Number Publication Date
CN1336917A CN1336917A (zh) 2002-02-20
CN1142910C true CN1142910C (zh) 2004-03-24

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008027455A Expired - Lifetime CN1142910C (zh) 1999-01-14 2000-01-06 酰胺化合物

Country Status (21)

Country Link
US (2) US6710043B1 (cg-RX-API-DMAC7.html)
EP (1) EP1140836B1 (cg-RX-API-DMAC7.html)
JP (2) JP3617454B2 (cg-RX-API-DMAC7.html)
KR (2) KR100520406B1 (cg-RX-API-DMAC7.html)
CN (1) CN1142910C (cg-RX-API-DMAC7.html)
AR (1) AR028812A1 (cg-RX-API-DMAC7.html)
AT (1) ATE502923T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP818099A0 (cg-RX-API-DMAC7.html)
BR (1) BRPI0008753B8 (cg-RX-API-DMAC7.html)
CA (1) CA2360360C (cg-RX-API-DMAC7.html)
CZ (1) CZ20012562A3 (cg-RX-API-DMAC7.html)
DE (1) DE60045759D1 (cg-RX-API-DMAC7.html)
ES (1) ES2363492T3 (cg-RX-API-DMAC7.html)
HK (1) HK1044337B (cg-RX-API-DMAC7.html)
HU (1) HU230422B1 (cg-RX-API-DMAC7.html)
IL (2) IL143841A0 (cg-RX-API-DMAC7.html)
RU (1) RU2208608C2 (cg-RX-API-DMAC7.html)
TR (1) TR200102038T2 (cg-RX-API-DMAC7.html)
TW (1) TWI229075B (cg-RX-API-DMAC7.html)
WO (1) WO2000042011A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200104713B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
AU2002224046A1 (en) * 2000-12-07 2002-06-18 Fujisawa Pharmaceutical Co. Ltd. Nootropic effect enhancer
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
ATE397861T1 (de) * 2002-12-06 2008-07-15 Dow Agrosciences Llc Synergistische zusammensetzungen
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20080009477A1 (en) * 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2081898A2 (en) * 2006-10-20 2009-07-29 Arete Therapeutics, INC. Adamantylurea compounds as soluble epoxide hydrolase inhibitors
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
MX2009011250A (es) 2007-04-20 2009-11-05 Senju Pharma Co Promotor de la formacion de neuritas.
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (cg-RX-API-DMAC7.html) * 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (cg-RX-API-DMAC7.html) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
EP0002401B1 (fr) * 1977-11-24 1980-12-10 Synthelabo Dérivés de naphtalène, leur préparation et leur application en thérapeutique
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
EP0255134B1 (en) 1986-07-31 1993-03-03 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
CN1052224C (zh) * 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
ATE204264T1 (de) * 1993-06-18 2001-09-15 Fujisawa Pharmaceutical Co Zwischenprodukt zur verwendung in der synthese und verfahren zur herstellung eines aminopiperazinderivates
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
EP0820452B1 (en) * 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
KR20000057303A (ko) * 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
EP0968201A2 (en) 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
JP3617454B2 (ja) 2005-02-02
KR20010093819A (ko) 2001-10-29
IL143841A (en) 2006-07-05
TR200102038T2 (tr) 2002-01-21
KR100520406B1 (ko) 2005-10-11
WO2000042011A1 (en) 2000-07-20
ATE502923T1 (de) 2011-04-15
JP2002534503A (ja) 2002-10-15
EP1140836A1 (en) 2001-10-10
HK1044337A1 (en) 2002-10-18
BRPI0008753B8 (pt) 2021-05-25
HUP0105108A3 (en) 2002-11-28
KR100525809B1 (ko) 2005-11-03
CZ20012562A3 (cs) 2001-11-14
KR20040063001A (ko) 2004-07-09
ES2363492T3 (es) 2011-08-05
AUPP818099A0 (en) 1999-02-11
ZA200104713B (en) 2002-09-09
TWI229075B (en) 2005-03-11
CA2360360C (en) 2009-09-08
HUP0105108A2 (hu) 2002-05-29
US20040014745A1 (en) 2004-01-22
AR028812A1 (es) 2003-05-28
IL143841A0 (en) 2002-04-21
BR0008753A (pt) 2001-11-06
US6710043B1 (en) 2004-03-23
BR0008753B1 (pt) 2013-11-12
CA2360360A1 (en) 2000-07-20
JP2004002414A (ja) 2004-01-08
HU230422B1 (hu) 2016-05-30
CN1336917A (zh) 2002-02-20
EP1140836B1 (en) 2011-03-23
HK1044337B (zh) 2004-11-26
RU2208608C2 (ru) 2003-07-20
DE60045759D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
CN1336917A (zh) 酰胺化合物
CN1063442C (zh) 氨基噻唑衍生物、含有它们的药物组合物及其用途
CN1152864C (zh) 具有pde-iv抑制活性的苯基菲啶类化合物
CN1243751C (zh) 用作抗变态反应药物的哌啶化合物
CN1038839C (zh) 一类环胺化合物的制备方法
CN1202093C (zh) 取代的杂环化合物
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1239952A (zh) 用作nos抑制剂的6-苯基吡啶基-2-胺衍生物
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1518546A (zh) 作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1197458A (zh) 具有磷酯酶a2抑制活性的吡咯烷衍生物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽-1(nk-1)拮抗剂的1-酰氨基-4-苯基-4-苄氧基甲基-哌啶衍生物和相关化合物
CN1617722A (zh) 烟碱或异烟碱苯并噻唑衍生物
CN1671666A (zh) Vegfr-2和vegfr-3抑制性的邻氨基苯甲酰胺吡啶化合物
CN101045727A (zh) 酪氨酸激酶抑制剂
CN101044135A (zh) 喹啉衍生物
CN1444573A (zh) 甲酰胺化合物及其作为人11cby受体拮抗剂的用途
CN1946402A (zh) 用作ccr3拮抗剂的哌啶衍生物
CN1288464A (zh) 作为orl-1受体激动剂的4-(2-酮-1-苯并咪唑啉基)哌啶化合物
CN1297442A (zh) 用作抗癌剂和抗增殖剂的5-氨基茚并[1,2-c]吡唑-4-酮类化合物
CN1662498A (zh) 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物
CN1114591C (zh) 环酰胺化合物
CN1286255A (zh) 新的吡啶化合物、其制备方法和含有它们的药物组合物
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060407

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20060407

Address after: Tokyo, Japan

Patentee after: ASTELLAS PHARMA Inc.

Address before: Osaka City, Osaka of Japan

Patentee before: Fujisawa Pharmaceutical Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20040324

CX01 Expiry of patent term